Conclusions
- A Whole-Transcriptome-Sequencing based CMS classifier allows for investigation in a large real-world clinic-genomic database.
- We found that MSS CMS1 CRC’s may derive benefit from immunotherapy.
- Additionally, CMS2 subgroup of right-sided tumors may derive benefit from cetuximab.
- Routine CMS subgrouping of CRC provides important treatment associations that should be further investigated.